Stock Price Movement and Market Context
On the day the new low was recorded, Albert David Ltd’s stock fell by 0.87%, underperforming the Pharmaceuticals & Biotechnology sector by 0.69%. The stock has been on a losing streak for two consecutive sessions, delivering a cumulative return of -2.14% over this period. Trading activity was confined within a narrow range of Rs.4.95, indicating limited volatility despite the downward pressure.
Technically, the stock is trading below all key moving averages, including the 5-day, 20-day, 50-day, 100-day, and 200-day averages. This broad-based weakness across short, medium, and long-term technical indicators underscores the prevailing bearish sentiment among market participants.
In contrast, the benchmark Sensex opened lower at 84,600.99, down 94.55 points (-0.11%), and was trading marginally down at 84,659.32 (-0.04%) during the same session. The Sensex remains close to its 52-week high of 86,159.02, just 1.77% away, and while it trades below its 50-day moving average, the 50DMA remains above the 200DMA, signalling a generally positive medium-term trend for the broader market.
Financial Performance and Profitability Concerns
Albert David Ltd’s financial results have been under pressure, contributing to the stock’s subdued performance. The company has reported negative results for four consecutive quarters, with Profit Before Tax (PBT) excluding other income at Rs. -0.44 crore, reflecting a decline of 109.80%. The net loss after tax (PAT) for the latest quarter stood at Rs. -3.30 crore, a deterioration of 118.3% compared to previous periods.
Operating cash flow for the year has also been negative, with the lowest recorded figure at Rs. -28.44 crore. This negative cash flow position highlights challenges in generating sufficient internal funds to support business activities and growth initiatives.
Over the last five years, the company’s operating profit has contracted at an annualised rate of -244.12%, indicating a sustained decline in core profitability. This long-term trend has weighed heavily on investor confidence and valuation.
Fundamentals that don't lie! This Small Cap from Trading shows consistent growth and price strength over time. A reliable pick you can truly count on.
- - Strong fundamental track record
- - Consistent growth trajectory
- - Reliable price strength
Valuation and Risk Profile
The company’s Mojo Score currently stands at 17.0, with a Mojo Grade of Strong Sell, upgraded from a Sell rating on 14 May 2025. This grading reflects the stock’s deteriorated fundamentals and heightened risk profile. The Market Cap Grade is rated at 4, indicating a relatively modest market capitalisation within its peer group.
Albert David Ltd’s stock has generated a negative return of -43.87% over the past year, significantly underperforming the Sensex, which posted a positive return of 8.18% during the same period. The stock’s 52-week high was Rs.1,412.15, underscoring the extent of the decline to the current low of Rs.730.05.
One notable risk factor is the company’s negative EBITDA, which signals that earnings before interest, taxes, depreciation, and amortisation are below zero. This metric, combined with the negative operating cash flow, suggests ongoing challenges in maintaining profitability and operational efficiency.
Despite these concerns, the company maintains a low average debt-to-equity ratio of zero, indicating minimal leverage and limited financial risk from borrowings. The majority shareholding remains with promoters, which may provide some stability in ownership structure.
Why settle for Albert David Ltd? SwitchER evaluates this Pharmaceuticals & Biotechnology micro-cap against peers, other sectors, and market caps to find you superior investment opportunities!
- - Comprehensive evaluation done
- - Superior opportunities identified
- - Smart switching enabled
Comparative Performance and Sector Positioning
Albert David Ltd’s performance has lagged not only the Sensex but also the broader BSE500 index over multiple time frames, including the last three years, one year, and three months. This consistent underperformance highlights the company’s challenges in maintaining competitive positioning within the Pharmaceuticals & Biotechnology sector.
The sector itself has shown relative resilience, with many peers maintaining stable or improving financial metrics. Albert David Ltd’s declining operating profit and negative quarterly results contrast with the sector’s overall trend, contributing to the stock’s weaker market sentiment.
While the stock’s narrow trading range in recent sessions suggests some consolidation, the prevailing technical and fundamental indicators point to continued caution among market participants.
Summary of Key Metrics
To summarise, Albert David Ltd’s stock has reached a new 52-week low of Rs.730.05, reflecting a year-to-date decline of nearly 44%. The company’s financial results have shown negative profitability for four consecutive quarters, with operating profit shrinking at an annualised rate exceeding 240% over five years. Negative EBITDA and operating cash flow further underline the challenges faced. Despite a low debt burden and promoter majority ownership, the stock’s valuation and performance metrics have deteriorated, resulting in a Strong Sell Mojo Grade as of mid-May 2025.
The broader market context, with the Sensex near its 52-week high and outperforming the stock, emphasises the divergence in performance between Albert David Ltd and the overall market. The stock’s technical indicators remain weak, trading below all major moving averages, and recent price action has been confined to a narrow range amid continued selling pressure.
Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year (MRP = Rs. 34,999) Start Today
